Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer (Q34333155)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

1 August 2017

Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer (English)

1 reference

Europe PubMed Central

1 August 2017

1 reference

based on heuristic

inferred from title

Alexandros Papachristofilou

object named as

Alexandros Papachristofilou

2

0 references

Mariola Fotin-Mleczek

11

object named as

Mariola Fotin-Mleczek

1 reference

Europe PubMed Central

1 August 2017

Ulrike Gnad-Vogt

14

object named as

Ulrike Gnad-Vogt

1 reference

Europe PubMed Central

1 August 2017

Karl-Josef Kallen

13

object named as

Karl-Josef Kallen

1 reference

Europe PubMed Central

1 August 2017

Regina Heidenreich

12

object named as

Regina Heidenreich

1 reference

Europe PubMed Central

1 August 2017

author name string

Martin Sebastian

1

1 reference

Europe PubMed Central

1 August 2017

Christian Weiss

3

1 reference

Europe PubMed Central

1 August 2017

Martin Früh

4

1 reference

Europe PubMed Central

1 August 2017

Richard Cathomas

5

1 reference

Europe PubMed Central

1 August 2017

Wolfgang Hilbe

6

1 reference

Europe PubMed Central

1 August 2017

Thomas Wehler

7

1 reference

Europe PubMed Central

1 August 2017

Gerd Rippin

8

1 reference

Europe PubMed Central

1 August 2017

Sven D Koch

9

1 reference

Europe PubMed Central

1 August 2017

Birgit Scheel

10

1 reference

Europe PubMed Central

1 August 2017

Alfred Zippelius

15

1 reference

Europe PubMed Central

1 August 2017

language of work or name

0 references

publication date

6 October 2014

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

14

1 reference

Europe PubMed Central

1 August 2017

748

1 reference

Europe PubMed Central

1 August 2017

https://scigraph.springernature.com/pub.10.1186/1471-2407-14-748

0 references

mRNA-based vaccines synergize with radiation therapy to eradicate established tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

A novel, disruptive vaccination technology: self-adjuvanted RNActive(®) vaccines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

Combining radiotherapy and cancer immunotherapy: a paradigm shift

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

Radiation as an immunological adjuvant: current evidence on dose and fractionation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

Role of T lymphocytes in tumor response to radiotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

Prognostic value of survivin in patients with non-small cell lung carcinoma: a systematic review with meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

Immunologic correlates of the abscopal effect in a patient with melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

Maximizing tumor immunity with fractionated radiation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

Harmonization of immune biomarker assays for clinical studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

Response definition criteria for ELISPOT assays revisited

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

Chemotherapy and radiotherapy: cryptic anticancer vaccines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

MUC1: a target molecule for cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

Palliative percutaneous radiotherapy in non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4195907

6 July 2018

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-14-748

21 January 2018

Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-14-748

21 January 2018

Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-14-748

21 January 2018

Cancer testis antigen and immunotherapy

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-14-748

21 January 2018

Expression of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltration.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-14-748

21 January 2018

Abscopal but desirable: The contribution of immune responses to the efficacy of radiotherapy

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-14-748

21 January 2018

Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25288198

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25288198

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition)

1 reference

https://pubmed.ncbi.nlm.nih.gov/25288198

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/25288198

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms

1 reference

https://pubmed.ncbi.nlm.nih.gov/25288198

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The impact of harmonization on ELISPOT assay performance

1 reference

https://pubmed.ncbi.nlm.nih.gov/25288198

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2407-14-748

1 reference

Europe PubMed Central

1 August 2017

Dimensions Publication ID

0 references

release_noiiy4x3lvgtba5nch6ix6b4hy

1 reference

https://api.fatcat.wiki/v0/release/noiiy4x3lvgtba5nch6ix6b4hy

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34333155&oldid=1843763243"